-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NGHqaWWtdI3JQnLLvfE4UsRVidUidWb76YhFTmoPGxstab/6H8SgZCLhTNhL1IvI
 pL64k7GKmhXSmXKx6IOsdA==

<SEC-DOCUMENT>0001130319-08-000494.txt : 20080613
<SEC-HEADER>0001130319-08-000494.hdr.sgml : 20080613
<ACCEPTANCE-DATETIME>20080612180604
ACCESSION NUMBER:		0001130319-08-000494
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080613
FILED AS OF DATE:		20080613
DATE AS OF CHANGE:		20080612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		08896739

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o41035e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of June 2008

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="44%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="44%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date:&nbsp;&nbsp;June&nbsp;12, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="top">
        <TD width="70%"><IMG src="o41035o4103500.gif" alt="Oncolytics Biotech Logo"></TD>
        <TD width="30%">210, 1167 Kensington Crescent N.W.<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt"><B><HR align="left" size="1" width="100%" noshade></B>

<DIV align="left" style="font-size: 11pt; margin-top: 12pt"><B>MEDIA ADVISORY</B>
</DIV>

<DIV align="center" style="font-size: 13pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. to Present at BIO 2008 International Convention</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt"><B>CALGARY, Alberta, &#151; June&nbsp;12, 2008 </B>&#151; Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), announced
today that Dr.&nbsp;Brad Thompson, President and CEO of Oncolytics, will participate in two separate
presentations at the BIO 2008 International Convention.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Dr.&nbsp;Thompson is scheduled to provide a corporate overview of the Company on Tuesday, June
17<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> at 3:30 p.m. PT at the BIO Business Forum.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">On Wednesday, June&nbsp;18<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> at 4:00 p.m. PT, Dr.&nbsp;Thompson is also scheduled to participate
as an invited speaker as part of a panel discussion entitled &#147;Canada: Your Global Partner for
Cancer Research Innovation.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">The Conference, which is expected to draw approximately 20,000 attendees, will be held at the San
Diego Convention Center June&nbsp;17<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> to June&nbsp;20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 15pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I/II
and Phase II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 15pt"><I>The presentation times are subject to change. This release and the presentations related thereto
contain forward-looking statements which involve known and unknown risks, delays, uncertainties and
other factors not under the Company&#146;s control and which may cause actual results, performance or
achievements of the Company to be materially different from the results, performance or
expectations implied by these forward-looking statements. Such risks and uncertainties include,
among others, the efficacy of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Company&#146;s quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to update these forward-looking statements.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center" style="margin-top: 6pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.<BR>
Cathy Ward<BR>
210, 1167 Kensington Cr NW<BR>
Calgary, Alberta T2N 1X7<BR>
Tel: 403.670.7377<BR>
Fax: 403.283.0858<BR>
<U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group<BR>
Nick Hurst<BR>
325, 300 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW<BR>
Calgary, AB, T2P 3C4<BR>
Tel: 403.538.4845<BR>
Fax: 403.237.6916<BR>
<U>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group<BR>
Erika Moran<BR>
11 Stone St, 3rd Floor<BR>
New York, NY 10004<BR>
Tel: 212.825.3210<BR>
Fax: 212.825.3229<BR>
<U>emoran@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 24pt">-30-
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o41035o4103500.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o41035o4103500.gif
M1TE&.#EA-`%!`+,*`/___\S,_\S,S)F9S)F9F9EFF69FF69F9C,S9C,`,___
M_P```````````````````"'Y!`$```H`+``````T`4$```3_4,E)J[U!",*)
M#E<HCF1IGFBJKFSKOG!\`D)Q)'BNXT<AR,"@<$@L&H_`@6'';.(,/Z1T2JU:
MKRX``>'L-A$$`'9,+IO/*"VW>S@8..VU$XRNV^_XH4"N0Q@&("("2GPY"%%Y
MB8J+B@!+3%`K`H\[!6*,F)F:4WL[8)<M`92&@9NFIZ@J`X4&H#`!-WV(J;2U
MM`.>LT"=AKJVO\!YN#JM1@%\A\'*RV<"E5.CR<S3U$B\.`-5T:[5W=XM`'S9
M5J,'W^?H**,%8Z,$Z?#Q%,XY!F3A.K[R^]1R"-Q6KIGC1Y`:@7QG#N;05[`A
M*GQ/ZOAS2+&60ARES-##P;"BQT1R_^S9B95@X,>3BC8FR-A,!TN4,,]0$GE'
MSKN8.,_(Z4CF(H*<0,>H3!1`!\"@2(M<I(EG9]*G1RC=S",5CX:K/$E@U0#5
MQ-:L%S1T\"#@I0*GB2Z:O'`Q@;2P.=:2`$!H3J02=;_\.;$TA3BM$RF,\K*#
M*06?*&H4,O3&K`2Z))T<\##!:$I#(]JZ9;A1;@@UA''\R[QXSE01:E-<2S`N
MK#^6D4/G.'U8AXE5LM]66.TV#A,$((KF6`3`-NK?^CJ7N.9'`"@:!'J,`!#Y
M3\8``R(#SQQ7Q>K6\_P!S/`UY%?G(=J2@*7CP(!9&PP8<*SR$+?X"*0I7V0\
M_1=?^XDPS/\31YU`DFX6,%>@`JFI`!$VNXF'`DFTD:">(/Z`%4)@)P282']L
MU9/A;MT)0LP+`R8`EDJ&U<8#"P^R-H&"*5"8PH4;&K)@"1)V6*(B(%J@UH.Z
M>6C!@3ORB)D)?!38X`HQ9D-CC;/=&*2+'*'8AP])*F`D'E=B:0YSB'PY@7`1
MO7"B"04@%.*+X(C3(Y4X5,C=<#GB^0)OO15`68(_?JCGFR5)0*:A@9)8I0LJ
MV4EH`HX^"6-IHZU@(PHX6M!>$J7%14`I&_W$WZ!"_GBHF8@NV@*+?.D0::)0
M%E*II:J:D&D%FP:!7Q?L2!!F'4,=!Z>AXA4W+*`Y].I"'ZTNY-__L7'JZ,*E
MS>(@`H=$9%!`(;VZ=!FT%4CJI7BP4H`M"Y$Y5L$HCHG;`DF>T0FIE:1BJ2(G
M?$A`DH98]"6L6PGZLT:\,ZZYJ@[*BH!FH<\R#`.\+U!KZZ\*$*EN$*-(0$G"
M=TA<:KWC,D'P!.5<3$*;.8!G`9$=N8MNN1/66L*M$1JB<AHK!C:@J'FXV7`"
M(?`V\@2:_0$?(3?;ZQY+BO5RYV;G764@S%/72:^U(ZP&!GJ&*E9,!?@@,-E[
MH&00310+FXQ%J!92O-K09P[FA:.&QN;%U_^&IK8"$$\K<]L@@[V%;`FT:#=A
M\YG[MTSU:+5DT"&A$``!!I3FQGM>;3O'_V1[:]8%SR1L_`(E_*8*<(>5Z_5G
M@M%URL.G'Y]NA[$06B7U"^3=WM5T5^U=0>Y7[;APZ5(@MOOQ0O2-QH,<(^_\
MP2G7T9;OSU<?`I)G'-.X]=Q+@O`9Z78O?@JC$"]$6W2/KSX%%@O%[/KP9]U'
MET*L9GX9NM/R`50T<'W!-E583?HL(#<_^&X)`V3?X$K"!0.:0&[.`EQA))>Z
M_/"`?A(XB&%ND,!EW<LKHBF3[+12P34X"AD8W!,?6D2"&RBK$W";``=GP(4#
ME,(169I!#EL%NA0,(PPS4L%!Y#)#(^S0<0V,`CT>N!D*J"M&"-(#,F@%!@+8
MH(DF*")>,&*!&O^FX(@S<\M8^&4L%EJIBAW@0@=;`$83L<9J2R3!,)(F`BC2
M,0::F57,JF@#+N!M!%H$'$"\B((V<@>-JW.<C%YP$$0.;HTL,"1<@-8)*&#M
M3BE\#"LRN9S8'("3^II7P4390E*NAPL<HT?S1B!)_\3P>FZA7HB(:,HAM%)1
MFG3+)17F1TY2QQ-`A`$`4&8P*G+``+'X9!9KF;4;H#%UEOCB!YO5AFJ:<66:
MFPP<>M@V6D)R!;><QRZ)Z15GOH%R="@!,0T1S!4$0',[^";KQN(!ZFW`?!L8
M(R@YD,E\TE.>_B2+:A+I)8*>KYUSX<!N"'!'"V1`GQTJ#10PB)W#13$]?AB%
MTCIWT(/WP&=77Y!G1D>*`0@2K@E_)*E*6?!.U^4&H2N-Z:I2=U($^$"F.-W%
/`*(3&[%-IBPY#6H$```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
